For TCA, the onco-metabolites stabilize the hypoxia inducible factor 1, inhibit p53 expression, and increase glutaminolysis, glycolysis, or dysregulation of EMT, suggesting that these changes in p53 and TCA-related metabolites are important driving forces of cancer pathogenesis and progression [51]. The gene discussed is TP53; the disease is cancer.